Disclosure
Supplement
2024 ESG Action Report
UN
SDGs
TCFD
KPIs
Assurance
Statement
2
SASB
Index
AbbVie 2024 ESG Action Report | Disclosure Supplement
Contents
This supplement to the 2024 ESG Action Report contains AbbVie’s
update to the Sustainability Accounting Standards Board’s (SASB)
Biotechnology and Pharmaceuticals standard, our progress toward
the United Nations Sustainable Development Goals (UN SDGs), our
Task Force on Climate-related Financial Disclosure (TCFD) Report,
our 2024 ESG Key Performance Indicators (KPIs) and our Assurance
Statement from Ernst & Young LLP.
3 Sustainability Accounting Standards Board (SASB) Index
7 United Nations Sustainable Development Goals (UN SDGs)
9 Task Force on Climate-related Financial Disclosure (TCFD)
10 2024 ESG Key Performance Indicators (KPIs)
16 Assurance Statement from Ernst & Young, LLP
UN
SDGs
TCFD
KPIs
Assurance
Statement
AbbVie 2024 ESG Action Report | Disclosure Supplement 3
SASB
Index
Sustainability Accounting Standards Board (SASB) Index
Safety of Clinical Trial Participants
HC-BP-210a.1 Discussion, by region, of management process for ensuring quality and patient safety We require all our clinical studies to be conducted in a manner consistent with the ethical principles outlined in the World Medical
during clinical trials Association’s Declaration of Helsinki and to adhere to applicable standards set by the International Council for Harmonization of
Technical Requirements for Pharmaceuticals for Human Use. This includes adherence to Good Clinical Practice, Good Laboratory
Practice and Good Manufacturing Practice standards, which provide for the protection of rights, safety, well-being and ethical
treatment of trial participants. Additional details can be found in the Clinical Trials section of our 2024 ESG Action Report as well
as within the following:
• AbbVie’s Clinical Trial Protocol
• Registration of protocols & results reporting
• Clinical Trials
‒ Clinical Trial Protocol
• Our Commitment to Bioethics
HC-BP-210a.2 Number of inspections related to clinical trial management and pharmacovigilance that Additional details can be found in the U.S. Food & Drug Administration inspection classification database
resulted in (1) entity voluntary remediation or (2) regulatory or administrative actions
taken against the entity
HC-BP-210a.3 Total amount of monetary losses as a result of legal proceedings associated with If there are material legal proceedings associated with clinical trials in developing countries and public disclosure criteria are met,
clinical trials in developing countries details would be included in the 2024 Annual Report on Form 10-K.
Access to Medicines
HC-BP-240a.1 Description of actions and initiatives to promote access to health care products for At AbbVie, we believe patients need access to quality and affordable medicines. We continuously strive to improve health outcomes
priority diseases and in priority countries as defined by the Access to Medicine Index and increase access to health care services and our medicines for patients around the world, including through agreements with the
Medicines Patent Pool. AbbVie partners with stakeholders on interventions to help build health care capacity, increase the quality and
frequency of health worker training and educate patients about disease awareness, symptom management and treatment options.
Additional details can be found in the Patient Access and Affordability section of our 2024 ESG Action Report and in the following:
• Pricing and Access of Our Innovative Medicines
• AbbVie MPP HCV Agreement
• AbbVie MPP HIV Agreement
HP-BP-240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Additional details can be found in the World Health Organization Prequalification of Medical Products list.
Prequalification of Medicines Programme (PQP)
HC-BP-210a.1
HC-BP-210a.2
HC-BP-210a.3

HC-BP-240a.1
HP-BP-240a.2

UN
SDGs
TCFD
KPIs
Assurance
Statement
AbbVie 2024 ESG Action Report | Disclosure Supplement 4
SASB
Index
Affordability and Pricing
HC-BP-240b.2 Percentage change in: (1) weighted average list price and (2) weighted average net price Not reported
across product portfolio compared to previous reporting period
HC-BP-240b.3 Percentage change in: (1) list price and (2) net price of product with largest increase Not reported
compared to previous reporting period
Drug Safety
HC-BP-250a.1 Products listed in the public medical product safety or adverse event alert databases U.S. Food & Drug Administration (FDA) Med Watch Safety Alerts for Human Medical Products
HC-BP-250a.2 Number of fatalities associated with products U.S. Food & Drug Administration (FDA) Adverse Event Reporting System (FAERS) Public Dashboard
HC-BP-250a.3 (1) Number of recalls issued, (2) total units recalled 2024 FDA Class I Recalls: 0
2024 FDA Class II Product Recalls: 21
Learn about our system of standards, policies and procedures for product quality and safety in the Product Quality and Saf
[...]